|
|
| | MCA-Pro-Leu-Ala-Gln-Ala-Val-Dap(Dnp)-Arg-Ser-Ser-Ser-Arg-NH2 Basic information |
| Product Name: | MCA-Pro-Leu-Ala-Gln-Ala-Val-Dap(Dnp)-Arg-Ser-Ser-Ser-Arg-NH2 | | Synonyms: | ADAM-17 SUBSTRATE II, FLUOROGENIC;MCA-(ENDO-1A-DAP(DNP))-TNF-A (-5 TO +6) AMIDE (HUMAN);MCA-(ENDO-1A-DAP(DNP))-TNF-ALPHA (-5 TO +6) AMIDE (HUMAN);MCA-(ENDO-1A-DAP(DNP))-TUMOR NECROSIS FACTOR-ALPHA (-5 TO +6) AMIDE (HUMAN);MCA-PRO-LEU-ALA-GLN-ALA-VAL-DPA-ARG-SER-SER-SER-ARG-NH2;MCA-PLAQAVDAP(DNP)RSSSR-NH2;MCA-PLAQAV(DPA)RSSSR-NH2;FLUORESCENT PEPTIDE SUBSTRATE III | | CAS: | 192723-42-5 | | MF: | C69H103N23O24 | | MW: | 1638.7 | | EINECS: | | | Product Categories: | peptide | | Mol File: | 192723-42-5.mol |  |
| | MCA-Pro-Leu-Ala-Gln-Ala-Val-Dap(Dnp)-Arg-Ser-Ser-Ser-Arg-NH2 Chemical Properties |
| density | 1.56±0.1 g/cm3(Predicted) | | storage temp. | -15°C | | pka | 12.49±0.46(Predicted) | | Sequence | {Mca}-Pro-Leu-Ala-Gln-Ala-Val-{Dpa}-Arg-Ser-Ser-Ser-Arg-NH2 |
| | MCA-Pro-Leu-Ala-Gln-Ala-Val-Dap(Dnp)-Arg-Ser-Ser-Ser-Arg-NH2 Usage And Synthesis |
| Uses | Mca-PLAQAV-Dpa-RSSSR-NH2 is a fluorescent peptide and as one of fluorescent substrates of TNF-α converting enzyme (TACE; ADAM17), ADAM 9 and ADAM 10. Mca-PLAQAV-Dpa-RSSSR-NH2 is a substrate based on fluorescence resonance energy transfer, and its activity can be determined by the change of fluorescence intensity during pyrolysis[1]. | | IC 50 | ADAM10; ADAM17 | | References | [1] Yi Wang, et al. Protease assay method using site-specific fluorescence dye labeled protein as substrate. US9708638. 2017.
[2] Haga S, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85(3):551-5. DOI:10.1016/j.antiviral.2009.12.001
[3] Inoshima N, et al. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol. 2012 May;132(5):1513-6. DOI:10.1038/jid.2011.462
[4] Liang T, et al. KID24, an antibody directed against ADAM9, is a potent inhibitor of tumor growth in vivo[J]. Molecular Cancer Therapeutics, 2007, 6(11_Supplement): C32-C32. |
| | MCA-Pro-Leu-Ala-Gln-Ala-Val-Dap(Dnp)-Arg-Ser-Ser-Ser-Arg-NH2 Preparation Products And Raw materials |
|